Headquartered in Chicago, IL Fiscal year ends December NASDAQ: XERS xerispharma.com
Xeris Biopharma Holdings, Inc. is an endocrine and rare disease biopharmaceutical company that develops and commercializes medicines for serious diseases with significant unmet medical need. It has three commercial products:
- **Recorlev (levoketoconazole):** a cortisol synthesis inhibitor for endogenous Cushing's syndrome and the company's largest and fastest-growing product.
- **Gvoke:** a ready-to-use liquid glucagon for severe hypoglycemia.
- **Keveyis (dichlorphenamide):** a therapy for primary periodic paralysis.
The company also earns royalty, contract and other revenue from partners using its XeriSol and XeriJect formulation technology platforms. Its lead pipeline asset is XP-8121, an investigational once-weekly subcutaneous levothyroxine injection for hypothyroidism, with the pivotal Phase 3 Cornerstone study slated to begin by year-end 2026 and potential launch in 2030. Multiple early-stage programs leverage its formulation platforms for Xeris and its partners. Updated
Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions in the penny stock category can produce eye-opening returns. While the profits…
Xeris Biopharma Holdings, Inc. is an endocrine and rare disease biopharmaceutical company that develops and commercializes medicines for serious diseases with significant unmet medical need.
The Wall Street consensus 12-month price target for XERS is $17.29.
